Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of ...

The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins ...

CRISPR Therapeutics has rallied on Casgevy progress, but overvaluation, early-stage pipeline, and lack of profits raise ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP stock is mainly due to a lack of pipeline updates, which is not sitting ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $32.65, marking a -0.03% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 5.98%.

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

View the latest CRISPR Therapeutics AG (CRSPN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

RGA Investment Advisors, an investment management company, has released its second-quarter 2025 investor letter. A copy of ...